Related references
Note: Only part of the references are listed.Rationale and design of a European epidemiological post-authorization safety study (PASS) program: rivaroxaban use in routine clinical practice
Luis Alberto Garcia-Rodriguez et al.
EXPERT OPINION ON DRUG SAFETY (2020)
Incidence of major and clinically relevant non-major bleeding in patients prescribed rivaroxaban for stroke prevention in non-valvular atrial fibrillation in secondary care: Results from the Rivaroxaban Observational Safety Evaluation (ROSE) study
Alison Evans et al.
PLOS ONE (2020)
Evaluation of the incidence of bleeding in patients prescribed rivaroxaban for the treatment and prevention of deep vein thrombosis and pulmonary embolism in UK secondary care: an observational cohort study
Alison Evans et al.
BMJ OPEN (2020)
Ascertainment and validation of major bleeding events in a primary care database
Ana Ruigomez et al.
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (2019)
A scheme based on ICD-10 diagnoses and drug prescriptions to stage chronic kidney disease severity in healthcare administrative records
Leif Friberg et al.
CLINICAL KIDNEY JOURNAL (2018)
XANTUS: a real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation
A. John Camm et al.
EUROPEAN HEART JOURNAL (2016)
Development and validation of an electronic frailty index using routine primary care electronic health record data
Andrew Clegg et al.
AGE AND AGEING (2016)
Rates of major bleeding with rivaroxaban in real-world studies of nonvalvular atrial fibrillation patients: a meta-analysis
Erin R. Weeda et al.
CURRENT MEDICAL RESEARCH AND OPINION (2016)
Cause of Death and Predictors of All-Cause Mortality in Anticoagulated Patients With Nonvalvular Atrial Fibrillation: Data From ROCKET AF
Sean D. Pokorney et al.
JOURNAL OF THE AMERICAN HEART ASSOCIATION (2016)
Effectiveness and safety of novel oral anticoagulants as compared with vitamin K antagonists in the treatment of acute symptomatic venous thromboembolism: a systematic review and meta- analysis
T. van der Hulle et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2014)
Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation
Manesh R. Patel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Share Paper
